Statement: In non-dialysis CKD patients, administration of anti-osteoporotic agents, such as active vitamin D, bisphosphonates, selective estrogen receptor modulators (SERMs), teriparatide, and denosumab may be considered because these may reduce fracture risk. The gene discussed is ESR1; the disease is chronic kidney disease.